Spyre Therapeutics Logo

Spyre Therapeutics

🇺🇸
SYRE
US00773J2024

Spyre Therapeutics is a US-based biotechnology company specializing in the development of innovative antibody therapies for inflammatory bowel diseases. Through cutting-edge research, the company optimizes treatment methods to improve patient care in a sustainable and meaningful way.

Next Quarterly Earnings

Thursday, November 5, 2026
CW 45
After-Hours
In 70 days

After-hours — typically from around 10:00 p.m. German time (after the US close at 4:00 p.m. New York time).

Quiet period starts on October 8, 2026

Stock Price

Frequently asked questions

When will Spyre Therapeutics report its next quarterly earnings?

Spyre Therapeutics is scheduled to report its next quarterly earnings on 11/05/2026. After-hours — typically from around 10:00 p.m. German time (after the US close at 4:00 p.m. New York time).

When did Spyre Therapeutics last report quarterly earnings?

Spyre Therapeutics last reported quarterly earnings on 8/4/2026 (Q2 2026). Earnings per share (EPS) came in at -0.36 USD.

How often has Spyre Therapeutics beaten expectations?

Spyre Therapeutics has beaten analyst EPS estimates in 4 of its last 5 evaluated quarters (beat rate: 80%).

How do I add the Spyre Therapeutics earnings dates to my calendar?

Use the 'Subscribe in calendar' button on this page to add all dates to Google Calendar, Apple Calendar or Outlook. Dates update automatically when they change.

All Dates

Q3 2026
Estimate:-$0.76
Actual:
Q2 2026
Beat
Estimate:-$0.76
Actual:-$0.36
Difference:+$0.40
Q1 2026
Missed
Estimate:-$0.67
Actual:-$0.74
Difference:-$0.07
Price reaction (1 day):+2.7 %
Price reaction (7 days):+8.6 %
Q4 2025
Beat
Estimate:-$0.71
Actual:-$0.70
Difference:+$0.01
Price reaction (1 day):+14.3 %
Price reaction (7 days):+14.1 %
Q2 2025
Beat
Estimate:-$0.74
Actual:-$0.15
Difference:+$0.59
Q1 2025
Beat
Estimate:-$0.71
Actual:-$0.49
Difference:+$0.22

Earnings statistics

Estimates vs. results

4/5
Quarters above estimates
80%
Beat rate
+8.8%
Avg. EPS surprise

Basis: 5 quarters with an analyst estimate and reported EPS.

Past price reactions are not a reliable indicator of future performance.

Company Information

Name
Spyre Therapeutics
Ticker Symbol
SYRE
ISIN
US00773J2024
Country
🇺🇸
USA
Sector